SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

$AKYA
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $AKYA alert in real time by email
SC 13G/A 1 akoyafinal.htm Enter title of document

          UNITED STATES
                 SECURITIES AND EXCHANGE COMMISSION
                        Washington, DC 20549

                            SCHEDULE 13G
            Under the Securities and Exchange Act of 1934
                         (Amendment #1)

                      Akoya Biosciences, Inc.
------------------------------------------------------------------
                         (Name of Issuer)

                      Common Stock, par value $0.00001 per share
------------------------------------------------------------------
                  (Title of Class of Securities)

                          00974H104
------------------------------------------------------------------
                          (CUSIP Number)

                        December 31, 2022
------------------------------------------------------------------
    (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

          [X]     Rule 13d-1 (b)
          [ ]     Rule 13d-1 (c)
          [ ]     Rule 13d-1 (d)

* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act, but shall
be subject to all other provisions of the Act (however, see
the Notes.)


CUSIP NO.  00974H104  13G


1     Name of Reporting Person
      PSC Capital Partners LLC

------------------------------------------------------------------
2     Check the Appropriate Box if a Member of a Group    (a)  [ ]
      			                                  (b)  [X]

------------------------------------------------------------------
3     SEC Use Only

------------------------------------------------------------------
4     Citizenship or Place of Organization
      Delaware

------------------------------------------------------------------



   Number of
                   5     Sole Voting Power
    Shares               2,717,360 shares
                   -----------------------------------------------
 Beneficially
                   6     Shared Voting Power
   Owned By              0 Shares
                   -----------------------------------------------
     Each
                   7     Sole Dispositive Power
   Reporting            2,717,360 shares
                   -----------------------------------------------
    Person
                   8     Shared Dispositive Power
     With                0 Shares
------------------------------------------------------------------
9     Aggregate Amount Beneficially Owned by Each Reporting Person
      2,717,360 Shares

------------------------------------------------------------------
10    Check if the Aggregate Amount in Row (9) Excludes Certain
      Shares  [X]

------------------------------------------------------------------
11    Percent of Class Represented by Amount in Row (9)
      7.2%

------------------------------------------------------------------
12    Type of Reporting Person
      IA
------------------------------------------------------------------

------------------------------------------------------------------
------------------------------------------------------------------

CUSIP NO.  00974H104  13G


1     Name of Reporting Person
      Piper Sandler Companies

------------------------------------------------------------------
2     Check the Appropriate Box if a Member of a Group    (a)  [ ]
      			                                  (b)  [X]

------------------------------------------------------------------
3     SEC Use Only

------------------------------------------------------------------
4     Citizenship or Place of Organization
      Delaware

------------------------------------------------------------------



   Number of
                   5     Sole Voting Power
    Shares               185 shares
                   -----------------------------------------------
 Beneficially
                   6     Shared Voting Power
   Owned By              19,616 Shares
                   -----------------------------------------------
     Each
                   7     Sole Dispositive Power
   Reporting             185 shares
                   -----------------------------------------------
    Person
                   8     Shared Dispositive Power
     With                19,616 Shares
------------------------------------------------------------------
9     Aggregate Amount Beneficially Owned by Each Reporting Person
      19,801 Shares

------------------------------------------------------------------
10    Check if the Aggregate Amount in Row (9) Excludes Certain
      Shares  [X]

------------------------------------------------------------------
11    Percent of Class Represented by Amount in Row (9)
      Less than 1%

------------------------------------------------------------------
12    Type of Reporting Person
      HC
------------------------------------------------------------------

------------------------------------------------------------------
------------------------------------------------------------------

CUSIP NO.  00974H104  13G


1     Name of Reporting Person
      PJC Capital LLC

------------------------------------------------------------------
2     Check the Appropriate Box if a Member of a Group    (a)  [ ]
      			                                  (b)  [X]

------------------------------------------------------------------
3     SEC Use Only

------------------------------------------------------------------
4     Citizenship or Place of Organization
      Delaware

------------------------------------------------------------------



   Number of
                   5     Sole Voting Power
    Shares               0 shares
                   -----------------------------------------------
 Beneficially
                   6     Shared Voting Power
   Owned By              19,616 Shares
                   -----------------------------------------------
     Each
                   7     Sole Dispositive Power
   Reporting             0 shares
                   -----------------------------------------------
    Person
                   8     Shared Dispositive Power
     With                19,616 Shares
------------------------------------------------------------------
9     Aggregate Amount Beneficially Owned by Each Reporting Person
      19,616 Shares

------------------------------------------------------------------
10    Check if the Aggregate Amount in Row (9) Excludes Certain
      Shares  [X]

------------------------------------------------------------------
11    Percent of Class Represented by Amount in Row (9)
      Less than 1%

------------------------------------------------------------------
12    Type of Reporting Person
      HC
-----------------------------------------------------------------

------------------------------------------------------------------
------------------------------------------------------------------

Item 1     (a)  Name of Issuer: Akoya Biosciences, Inc.

Item 1     (b)  Address of Issuer Principal Executive Offices:

		100 Campus Drive, 6th Floor,
		Marlborough, MA 01752

Item 2     (a)  Name of Persons Filing:

		This Schedule 13G is being filed jointly by the entities identified below (collectively, the Reporting Persons"):
			* PSC Capital Partners LLC
			* Piper Sandler Companies
			* PJC Capital LLC


Item 2     (b)  Address of Principal Business Office:

		800 Nicollet Mall Suite 900
                Minneapolis, MN 55402 - for all Reporting Persons

Item 2     (c)  Citizenship:

               	U.S. (Delaware) - For all Reporting Persons

Item 2     (d)  Title of Class of Securities: Common Stock, par value $0.00001 per share

Item 2     (e)  CUSIP Number:  00974H104

Item 3     If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c) of the Securities Exchange Act of 1934 as amended (the "Exchange 				Act"), check whether the person filing is a:

		(a)  [ ]  Broker or dealer registered under Section 15 of the Exchange Act;

		(b)  [ ]  Bank as defined in Section 3(a)(19) of the Exchange Act;

		(c)  [ ] Insurance company as defined in Section 3(a)(19) of the Exchange Act;

		(d)  [ ] Investment company registered under Section 8 of the Investment Company Act of 1940;

		(e)  [X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

		(f)  [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

		(g)  [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

		(h)  [ ] A savings association as defined in Section 3(b) of teh Federal Deposit Insurance Act (12 U.S.C. 1813);

		(i)  [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14)
			of the Investment Company Act of 1940;

		(j)  [ ] A non-US instituition in accordance with Rule 240.13d-1(b)(1)(ii)(J);

		(k)  [ ] A Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance
			with Rule 240.13d-1(b)(ii)(J), please specify the type of instition.

Item 4     Ownership

           (a)  through (c)

	The information in Items 1 and 5 through 11 on the cover pages to this Schedule 13G are hereby incorporated by reference.  Piper Sandler Companies is the parent corporation of PSC Capital Partners LLC and PJC Capital LLC (PJC Capital LLC is not a control person of PSC Capital
	Partners LLC). As to Piper Sandler Companies and PSC Capital Partners LLC, this Schedule 13G reflects a disaggregation of beneficial ownership between the two entities, as defined in Section 13(d) and 13(g) of the Exchange Act. As to Piper Sandler Companies and PJC Capital LLC, this Schedule 13G reflects that Piper Sandler Companies is deemed to share voting and dispositive power over the shares held by PJC Capital LLC, in accordance with Section 13(d) and 13(g) of the Exchange Act and the rules promulgated thereunder.

	This Schedule 13G is not an admission that any of Reporting Persons are the beneficial owner of the securities covered by this report, except as 	expressly stated herein, and each of the Reporting Persons disclaims beneficial ownership of the securities covered by this statement that are not expressly reported by them as being beneficially owned, pursuant to Exchange Act Rule 13d-4.

Item 5     Ownership of Five Percent or Less of a Class:

	   Not applicable.

Item 6     Ownership of More than Five Percent on Behalf of Another Person:

	   Not applicable.

Item 7     Identification and Classification of the Subsidiary
           Which Acquired the Security being Reported on by the
           Parent Holding Company:

	   Not applicable.

Item 8     Identification and Classification of Members of the Group:

	   Not applicable.

Item 9     Notice of Dissolution of the Group:

	   Not applicable.

Item 10    Certification

           By signing below I certify that, to the best of my knowledge and belief, the securities referred to
           above were acquired and are held in the ordinary course of business and were not acquired and are
           not held for the purpose of or with the effect of changing or influencing the control of the issuer
           of the securities and were not acquired and are not held in connection with or as a participant
           in any transaction having such purposes or effect.

	   List of Exhibits

		Exhibit 99.1  Joint Filing Agreement - filed herewith


	   SIGNATURE

	   After reasonable inquiry and to the best of my knowledge and
	   belief, I certify that the information set forth in this
	   statement is true, complete and correct.


			PSC CAPITAL PARTNERS LLC

			Date: 2/14/23

			By /s/ Theodore J. Christianson
			----------------------------------
			Signature

			Name/Title Theodore J. Christianson, CEO



			PIPER SANDLER COMPANIES

			Date: 2/14/23

			By /s/ Timothy L. Carter
			----------------------------------
			Signature

			Name/Title Timothy L. Carter, CFO



			PJC CAPITAL LLC

			Date: 2/14/23

			By /s/ Timothy L. Carter
			----------------------------------
			Signature

			Name/Title Timothy L. Carter, CFO








Get the next $AKYA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AKYA

DatePrice TargetRatingAnalyst
11/15/2024$7.00 → $5.00Buy → Hold
Craig Hallum
8/6/2024Overweight → Equal-Weight
Morgan Stanley
8/6/2024Buy → Neutral
BTIG Research
8/6/2024Overweight → Neutral
JP Morgan
6/21/2024$7.50Buy
Craig Hallum
12/14/2023Neutral
Guggenheim
7/5/2023$18.00Overweight
JP Morgan
2/2/2023$14.00Buy
UBS
More analyst ratings

$AKYA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

    Tikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (NASDAQ:QTRX) ("Quanterix" or the "Company"), today announced that it intends to vote AGAINST the Company's proposed merger with Akoya Biosciences, Inc. ("Akoya") (NASDAQ:AKYA) at the upcoming Quanterix Special Meeting of shareholders. As a significant investor in the Company since 2018, Tikvah believes the proposed merger is not in the best interest of Quanterix's shareholders. Tikvah echoes the public comments made by other investors opposing the merger, including that the proposed transaction undervalues Quanterix's shares, there would

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

    Believes Proposed Transaction with Akoya Significantly Undervalues Quanterix Encourages Shareholders to Vote Against Transaction to Protect Long-Term Value of their Investment Kent Lake PR LLC ("Kent Lake") is a holder of 7.47% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company's proposed transaction (the "Transaction") with Akoya Biosciences ("Akoya") (NASDAQ:AKYA), and has also nominated three highly qualified, independent candidates for election to the Company's Board of Directors (the "Board"). Kent Lake urges Quanterix management to addres

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

    MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AKYA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AKYA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AKYA
SEC Filings

See more

$AKYA
Leadership Updates

Live Leadership Updates

See more
  • Akoya Biosciences Announces Leadership Transition

    Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

    MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

    MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AKYA
Financials

Live finance-specific insights

See more
  • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

    MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

    Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Akoya Biosciences Reports Third Quarter 2024 Financial Results

    MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. "Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and en

    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$AKYA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more